1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsProtecting Human Genomic Data When Developing Generative Artificial Intelligence Tools and Applications is sponsored by NIH. Guidance on protecting human genomic data in AI tool development.
Get alerted about grants like this
Save a search for “NIH” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
NOT-OD-25-081: Protecting Human Genomic Data when Developing Generative Artificial Intelligence Tools and Applications Protecting Human Genomic Data when Developing Generative Artificial Intelligence Tools and Applications August 27, 2014 - NIH Genomic Data Sharing Policy. See notice NOT-OD-14-124 .
August 27, 2014 - Request for Information on Responsibly Developing and Sharing Generative Artificial Intelligence Tools Using NIH Controlled Access Data. See notice NOT-OD-25-118 . Office of The Director, National Institutes of Health ( OD ) Artificial intelligence (AI) tools and applications are proving to be transformative for driving new biomedical research advances.
While development and use of generative AI is becoming increasingly prevalent, NIH urges the research community to remain vigilant of potential risks of inadvertent data disclosure when sharing AI tools and applications.
Specifically, NIH reminds researchers that: The Genomic Data Sharing (GDS) Policy and the subsequent Data Use Certification (DUC) Agreement prohibit users from distributing controlled-access data (including genomic or associated data) or their Data Derivatives to any entity or individual not identified in their Data Access Request without appropriate written approvals from the NIH.
Sharing, retaining, or training generative AI models using controlled-access human genomic data may risk disclosing controlled-access data and, thus, violates the Non-Transferability provision of the DUC.
The GDS Policy and the Genomic Data User Code of Conduct state that sharing controlled-access data with public generative AI tools (e.g., third party tools) via prompts or other user interfaces is in violation of the provision on Non-Transferability, and by extension, the DUC.
Similarly, Developers requesting access to controlled-access data for developer work, as defined in NOT-OD-24-157 , are bound by the Non-Transferability provision in the Developer Terms of access . Additionally, NIH considers generative AI models, including model parameters, developed by Approved Users of controlled-access data to constitute Data Derivatives as defined in the DUC provision 14. Definitions.
NIH intends to provide future guidance on the responsible use and sharing of generative AI models and controlled-access data.
Until that guidance is issued, as described in the DUC, Approved Users of controlled-access data may continue to develop generative AI models using the controlled-access data so long as the use is approved by NIH, but (1) may not share the model, including model parameters, except with collaborators who are also Approved Users and (2) may not retain the generative AI model, including model parameters, upon closeout of the project as instructed in provision 13.
Termination and Data Destruction of the DUC. Approved Users may request to renew any expiring projects in order to continue using generative AI models until further guidance is issued. For additional information on using controlled-access data responsibly, see the principles described in Using Genomic Data Responsibly Under the NIH Genomic Data Sharing Policy and the AI in Research: Policy Considerations and Guidance .
Please direct all inquiries to: NIH Office of Science Policy Weekly TOC for this Announcement NIH... Turning Discovery Into Health ®
Based on current listing details, eligibility includes: U. S. institutions and organizations. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Varies Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is rolling deadlines or periodic funding windows. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
Science Education Partnership Award (SEPA) is sponsored by National Institute of General Medical Sciences (NIGMS), National Institutes of Health (NIH). The Science Education Partnership Award (SEPA) Program funds grants for innovative educational programs that create partnerships among biomedical and clinical researchers and K-12 teachers and schools, museums and science centers, media experts, and other educational organizations. The program aims to improve STEM literacy through innovative P-12 and informal science education. Projects can be classroom-based or informal science education projects in venues such as science centers, museums, and libraries.
Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Required) is sponsored by National Institutes of Health (NIH). This K23 award supports individuals with a clinical doctoral degree who propose to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development in patient-oriented research.
Social disconnection and Suicide Risk in Late Life (R01 Clinical Trial Optional) is sponsored by National Institute of Mental Health (NIMH), National Institutes of Health (NIH). This funding opportunity is a companion to the R21 mechanism and also aims to stimulate research to understand the link between social disconnection and suicidal thoughts and behaviors in late life. It focuses on identifying mechanisms by which social disconnection confers risk for, and social integration protects against, suicidal thoughts and behaviors in late life. This R01 mechanism is appropriate for applications with preliminary data.
NIH's accelerating use of multiyear-funded grants — 601 awards worth $402 million in the first half of FY26, against just 146 awards worth $75 million in the same window of FY24 — has produced a fiscal contraction at research universities that has begun cascading into PhD admissions. AAU member institutions are admitting smaller graduate cohorts than they did in 2024 or 2025, with downstream consequences for the biomedical workforce, lab continuity, and the foreign-student pipeline through 2030. Why the contraction is structural rather than cyclical, and what universities, PIs, and prospective trainees should be doing in the second half of 2026.
Read articleNIH has no active SBIR or STTR omnibus solicitations for the first time in a decade. The FY26 reset reposts the omnibus series on June 1 with a September 8 deadline and a quietly historic change — Direct-to-Phase II STTR awards. Here is the strategy.
Read articleNIH posted PAR-27-032 — Maximizing Investigators' Research Award for Early Stage Investigators — on May 12 as the first NOFO under the HHS SimplerNOFO initiative. Plain language, checklists, restructured sections, and explicit guidance replace the dense traditional NIH announcement. What the redesign means for grant writing strategy across HHS and which NOFOs are next in line.
Read article